Please do not leave this page until complete. This can take a few moments.
The Food and Drug Administration has approved a Pfizer vaccine for pregnant women aimed at preventing Respiratory Syncytial Virus, or RSV, in infants.
RSV typically causes symptoms such as coughing, sneezing, fever and wheezing, but it can lead to more serious complications like pneumonia, according to the U.S. Centers for Disease Control and Prevention.
The disease is a leading cause of hospitalization in children under the age of 1, according to Pfizer, which is based in New York and has a research facility in Groton.
The company’s vaccine, called Abrysvo, is now the first and only U.S.-approved maternal vaccine to help protect infants at birth through the age of 6 months from lower respiratory tract disease (LRTD) caused by RSV, according to Pfizer.
The vaccine is designed to be given to pregnant women who are at 32 to 36 weeks’ gestation.
The approval follows a Phase 3 clinical trial which included more than 7,000 pregnant women and their infants, according to Pfizer.
Annaliesa Anderson, Pfizer’s senior vice president and chief scientific officer, vaccine research and development, said the approval “marks a significant milestone” for public health and the scientific community.
“Today, a long-sought-after goal to deliver a maternal vaccine that will help protect infants 6 months of age or younger – when they are at greatest risk of possible serious consequences from RSV – has been achieved,” Anderson said, in an announcement this week.
Dr. Eric A.F. Simões of Children’s Hospital Colorado, who specializes in pediatric infectious diseases, said newborns and young infants’ immune systems are still developing, and often aren’t strong enough yet to defend against infections.
Maternal immunization via the new vaccine is expected to provide protection from birth, according to Pfizer.
In May, the FDA approved the vaccine for preventing lower respiratory tract disease caused by RSV in people aged 60 and older.
Pfizer has started clinical trials to evaluate Abrysvo for preventing RSV in children under age 2, and for high risk adults, such as those with asthma, between the ages of 18 and 60.
The Hartford Business Journal 2025 Charity Event Guide is the annual resource publication highlighting the top charity events in 2025.
Learn moreHartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
SubscribeDelivering vital marketplace content and context to senior decision-makers throughout Connecticut ...
All Year Long!
The Hartford Business Journal 2025 Charity Event Guide is the annual resource publication highlighting the top charity events in 2025.
Hartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
Delivering vital marketplace content and context to senior decision-makers throughout Connecticut ...
All Year Long!
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
This website uses cookies to ensure you get the best experience on our website. Our privacy policy
To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy
0 Comments